Jardiance sglt2
Pro Research Analysisby 
Searched over 200M research papers for "jardiance sglt2"
Empagliflozin (Jardiance) and SGLT2 Inhibitors: A Comprehensive Overview
Introduction to Empagliflozin (Jardiance) and SGLT2 Inhibitors
Empagliflozin, marketed under the brand name Jardiance, is a potent and highly selective sodium-glucose cotransporter-2 (SGLT2) inhibitor. It is widely used for the treatment of type 2 diabetes mellitus (T2DM) and has been approved in various regions, including the EU, USA, and Japan . SGLT2 inhibitors work by inhibiting glucose reabsorption in the renal tubules, promoting glucosuria, and thereby reducing blood glucose levels independently of insulin .
Glycemic Control and Weight Management
Empagliflozin has demonstrated significant efficacy in lowering fasting and postprandial glycemia, as well as reducing glycated hemoglobin (HbA1c) levels. Clinical trials have shown that empagliflozin can reduce HbA1c by approximately 0.8% without causing hypoglycemia, except in patients already on insulin or sulfonylureas Scheen2015Scott2014. Additionally, empagliflozin promotes weight loss, with patients typically losing around 2 kg, and lowers blood pressure by approximately 4 mm Hg systolic and 2 mm Hg diastolic Scheen2015Scott2014.
Cardiovascular and Renal Benefits
One of the most notable benefits of empagliflozin is its cardioprotective and renoprotective properties. The EMPA-REG OUTCOME trial demonstrated that empagliflozin significantly reduces the risk of cardiovascular death and hospitalization for heart failure in patients with T2DM and established cardiovascular disease Frampton2018Scheen2015Arun2022. Furthermore, empagliflozin has been shown to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with chronic kidney disease (CKD) .
Safety Profile and Adverse Effects
Empagliflozin is generally well tolerated, with most adverse events being mild to moderate in intensity. Common side effects include mycotic genital infections, particularly in women, and a slight increase in mild urinary tract infections Scheen2015Scott2014. However, a rare but serious adverse effect associated with SGLT2 inhibitors, including empagliflozin, is euglycemic diabetic ketoacidosis (DKA). This condition can occur under certain circumstances such as acute illness, decreased carbohydrate intake, or discontinuation of insulin Waylen2019Dyatlova20219.
Use in Special Populations
Empagliflozin has recently been approved for use in children aged 10 years and older to improve glycemic control in T2DM . This expands the therapeutic options for managing diabetes in pediatric populations, providing a novel insulin-independent mechanism of action.
Conclusion
Empagliflozin (Jardiance) is a valuable treatment option for managing type 2 diabetes mellitus, offering significant benefits in glycemic control, weight management, and cardiovascular and renal protection. While generally well tolerated, it is important to monitor for potential adverse effects such as euglycemic DKA. Given its comprehensive benefits, empagliflozin is particularly beneficial for patients with high cardiovascular risk or chronic kidney disease.
Sources and full results
Most relevant research papers on this topic